The short answer
The principal reported mechanism is upregulation of neurotrophin gene expression. Rodent studies have reported increased BDNF and NGF expression in hippocampus and frontal cortex, with downstream signalling through the TrkB and TrkA receptors. Additional reported activity includes dopaminergic and serotonergic modulation.
Key facts
- Primary reported targets
- BDNF, NGF
- Downstream receptors
- TrkB (BDNF), TrkA (NGF)
- Regions studied
- Hippocampus, frontal cortex
- Model organism
- Rat
- Key reference
- Brain Res 2006 (PMID 16996037)
- Also reported
- Dopaminergic, serotonergic modulation
- Steroidogenic activity
- None (unlike parent ACTH)
What neurotrophins are
Brain-derived neurotrophic factor and nerve growth factor are growth factors that support neuronal survival, differentiation and synaptic plasticity. BDNF signals through the TrkB receptor, NGF through TrkA. Both are involved in activity-dependent plasticity, which is why expression changes in these genes attract attention in cognitive and neuroprotection research.
What the studies actually measured
The 2003 Doklady Biological Sciences paper reported that Semax stimulates BDNF expression across regions of the rat brain in vivo. The 2006 Brain Research study reported regulation of both BDNF and trkB expression in the rat hippocampus. A 2010 Journal of Molecular Neuroscience paper compared the temporal dynamics of NGF and BDNF gene expression across hippocampus and frontal cortex. These are gene- and protein-expression measurements in rodents, not behavioural or clinical endpoints.
Research material referenced
Semax 10mg, third-party HPLC tested
Expression is upstream of effect
This distinction is worth holding onto. Demonstrating that a compound raises BDNF messenger RNA in rat hippocampus establishes that it does something measurable to that pathway. It does not by itself establish a functional consequence, and it certainly does not establish one in a different species. The gap between an expression change and an outcome is where a great deal of peptide literature quietly overreaches.
The wider transcriptional picture
A 2014 BMC Genomics study took a broader approach, reporting that Semax affects expression of genes related to the immune and vascular systems in a rat model of focal cerebral ischaemia. That is a considerably wider signature than neurotrophins alone, and it suggests the compound's transcriptional effects are not confined to a single pathway.
What separates it from ACTH
The parent hormone acts on melanocortin receptors and stimulates adrenal steroidogenesis. Semax does not, because the residues responsible were replaced by Pro-Gly-Pro. Whatever central activity the peptide has is therefore not secondary to a corticosteroid response, which is the main confound the design was intended to eliminate.
What remains unresolved
No receptor has been definitively established as the primary target. The mechanistic literature describes downstream consequences (expression changes, neurotransmitter modulation) more confidently than it describes the initiating molecular event. That is a real gap, not a summary omission.
Frequently asked questions
Does Semax have a known receptor?
No primary receptor has been definitively established. The literature characterises downstream effects more clearly than the initiating interaction.
Were the BDNF studies done in humans?
No. The neurotrophin expression work is rodent, principally rat hippocampus and frontal cortex.
Does Semax raise cortisol like ACTH?
No. The Pro-Gly-Pro substitution removes the steroidogenic activity of the parent hormone.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSemax regulates BDNF and trkB expression. Brain Res 2006 (PMID 16996037)pubmed.ncbi.nlm.nih.gov
- PubMedSemax stimulates BDNF expression in rat brain. Dokl Biol Sci 2003 (PMID 14556513)pubmed.ncbi.nlm.nih.gov
- PubMedNGF and BDNF expression dynamics. J Mol Neurosci 2010 (PMID 19662538)pubmed.ncbi.nlm.nih.gov
- PubMedSemax and gene expression in focal ischaemia. BMC Genomics 2014 (PMID 24661604)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Semax (ACTH Fragment Peptide) articles
- Semax in the Published LiteratureAbout 231 indexed PubMed records. The mechanistic work is rodent, the clinical work largely Russian-language. How to read an unevenly distributed evidence base.
- Semax Regulatory Status: Registered Where, and Why It MattersSemax is a registered medicine in the Russian Federation and holds no MHRA, EMA or FDA authorisation. What a national registration does and does not mean.
- Semax CAS Number and Chemical IdentitySemax CAS Registry Number is 80714-61-0, PubChem CID 9811102, UNII I5FAL2585H. Identifiers for checking a certificate against the literature.
- Semax Storage, Stability and ReconstitutionSemax is proline-stabilised and lacks cysteine, so handling is simpler than most - but its single methionine oxidises. Storage and reconstitution.
- Semax vs Selank: How They DifferSemax derives from ACTH, Selank from tuftsin. Both use a Pro-Gly-Pro extension and both came from the same institute, but their parent peptides differ entirely.